A Phase Ib trial investigated the combination therapy of gefitinib and the oral class I PI3K inhibitor BKM120 in patients with advanced NSCLC, focusing on those with alterations in PI3K pathway molecules and known overexpression of EGFR (NCT01570296) (National Cancer Centre, Singapore, 2012). Here, PIK3CG is linked to non-small cell lung carcinoma.